fremanezumab has completed phase iii trials and is under review by the fda to prevent migraine and
.ai-based software may help predict risk of dementia
.
.
.
.
.
the report "correctly points out that there really was no playbook for dealing with what was an unprecedented health crisis," san diego mayor kevin faulconer said.
.